Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. SEC filings page for ticker WGSWW provides access to the company’s U.S. regulatory disclosures, including current reports, annual and quarterly reports, proxy statements and documents describing its warrant securities. WGSWW represents warrants to purchase one share of GeneDx Holdings Corp. Class A common stock at a specified exercise price per share, and the detailed terms of these warrants are set out in registration statements and related filings.
Through these filings, GeneDx outlines its status as a Delaware corporation, its listing of warrants on The Nasdaq Stock Market LLC, and material corporate events such as changes in the size and composition of its Board of Directors. For example, a Form 8-K describes the appointment of a new Class I director, the increase in board size from seven to eight directors, the application of the Non-Employee Director Compensation Policy, and the company’s intention to enter into a standard form indemnity agreement with the director.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy reports, helping readers understand topics such as warrant terms, governance changes and references to compensation policies without reading every page. Real-time updates from the SEC’s EDGAR system ensure that new GeneDx filings appear promptly, while Form 4 and other insider-related reports can be reviewed to see how directors and officers interact with the company’s securities when such filings are made.
Users interested in GeneDx’s health insights and genomic focus can also use the filings to see how the company describes its activities, risk factors and data resources over time. The combination of original documents and AI-generated explanations makes it easier to interpret complex legal and financial language in the context of the WGSWW warrants and the underlying issuer.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.
The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
GeneDx Holdings Corp. (WGS) Form 4 shows Chief Financial Officer Kevin Feeley reported transactions on 09/16/2025 related to the vesting and settlement of restricted stock units (RSUs). 7,197 RSUs were treated as vested and settled for no cash consideration, and the Reporting Person triggered a sell-to-cover transaction that sold 3,728 shares at a weighted average price of $121.4727 to satisfy tax withholding. After these transactions, Mr. Feeley directly beneficially owned 8,755 shares of Class A common stock.
In addition to direct holdings, the filing discloses contingent rights to receive 124,633 RSU shares and options to purchase 27,152 shares, which vest over time per their terms. The sale is described as non-discretionary and solely to cover withholding obligations.
Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.
GeneDx Holdings Corp. reported that its Board of Directors appointed Thomas Fuchs, Dr.sc. as a Class I director, effective September 17, 2025. His term will run until the company’s 2028 Annual Meeting of Stockholders, and the Board size increased from seven to eight directors with this appointment.
Dr. Fuchs is the SVP and Chief AI Officer at Eli Lilly and Company, where he leads artificial intelligence initiatives across drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He has previously held senior academic and research roles in AI and computational pathology and founded several companies, including Paige AI.
Under GeneDx’s Non-Employee Director Compensation Policy, Dr. Fuchs will receive an initial restricted stock unit grant valued at $420,000, vesting over three years, subject to his continued service. The company also plans to enter into its standard form indemnity agreement with him, and there are no related-party transactions requiring disclosure in connection with his appointment.
Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.
The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.
FAQ
What is the current stock price of GeneDx Holdings (WGSWW)?
